Affinity Asset Advisors’s ProQR Therapeutics PRQR Stock Holding History

Affinity Asset Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	5,543,936 +3,089,658	+126%	+$5.09M	0.47%	60
2026 Q1	$3.98M	Hold	2,454,278	–	–	0.21%	82
2025 Q4	$4.96M	Sell	2,454,278 -1,145,722	-32%	-$2.68M	0.28%	66
2025 Q3	$7.67M	Buy	3,600,000 +100,488	+3%	+$220K	0.67%	42
2025 Q2	$7.14M	Buy	3,499,512 +215,000	+7%	+$350K	0.98%	29
2025 Q1	$4.37M	Buy	3,284,512 +459,512	+16%	+$978K	0.42%	49
2024 Q4	$7.49M	Buy	+2,825,000	New	+$8.97M	1%	29

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Affinity Asset Advisors's PRQR Position: Q2 2026 in Review

Affinity Asset Advisors increased its ProQR Therapeutics (PRQR) stake by 126% in Q2 2026, buying an estimated $5.09M and bringing the position to 5,543,936 shares worth $10.3M. The position accounts for 0.47% of the portfolio, ranked #60.

Affinity Asset Advisors first reported a position in PRQR in Q4 2024 and has held it in 7 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

Affinity Asset Advisors held 5,543,936 shares of ProQR Therapeutics worth $10.3M as of Q2 2026.
Affinity Asset Advisors bought 3,089,658 ProQR Therapeutics shares in Q2 2026, an estimated $5.09M.
ProQR Therapeutics made up 0.47% of Affinity Asset Advisors's portfolio in Q2 2026, its #60 holding.
Affinity Asset Advisors first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 7 quarters since.
70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.